Drug resistance represents a primary obstacle, which hinders the clinical success of anticancer pharmacotherapy. Our research is mainly focused on the role of pharmacokinetic mechanisms in anticancer drug resistance. In addition, we investigate the possible utilization of drug interactions to overcome this phenomenon. In our work, we collaborate with several research teams and use a variety of in silico, in vitro, and ex vivo techniques to fulfill scientific aims.